Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kova vs Luci

Kova
Graded #498

Lower grade

vs+26.700000000000003
Luci
Graded #101

Higher grade

The verdict

Luci takes it — 71/100 to 44.3/100.

Luci grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luci is a budget-focused GLP-1 telehealth platform offering compounded medications with upfront pricing: compounded semaglutide as low as $99/month and compounded tirzepatide as low as $145/month, plus oral…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLuci +64
20
84
Dose & formulationLuci +35
40
75
Clinical oversightEven
71
71
Labs & monitoringLuci +1
52
53
FulfillmentLuci +9
61
70
Contract termsLuci +30
25
55
Kova · left barLuci · right bar

The numbers

MetricKovaLuci
WeighScore44.3/10071/100
GradeCC
Scorecard rank#498#101
SemaglutideNot disclosed$99/mo (starting dose, promotional rate, compounded)
TirzepatideNot disclosed$145/mo (starting dose, promotional rate, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Kova

Graded #498 · C

Strengths

  • Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
  • Medication is included in the plan price, with no separate pharmacy charge
  • States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
  • Companion app tracks weight, protein and side effects, with medication schedule reminders
  • You are not charged unless a provider approves treatment

Where it loses points

  • At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
  • The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
  • Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
  • Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
  • No pharmacy or prescribing medical group is named anywhere on the site
Luci

Graded #101 · C

Strengths

  • Budget-friendly compounded GLP-1 pricing (compounded semaglutide as low as $99/month, tirzepatide as low as $145/month)
  • Multiple formats: compounded semaglutide and tirzepatide injections plus oral semaglutide and tirzepatide pill kits
  • Upfront pricing with no insurance required and a fast 3-minute questionnaire to start
  • Care delivered through DrTelx, an independent US telehealth medical group, with ongoing support and dose optimization
  • HIPAA-compliant platform with a large self-reported member base (50,000+)

Where it loses points

  • Compounded medications are not FDA-approved for weight loss (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Available only in select U.S. states, and the full state list is not published
  • The compounding pharmacy partner is not named
  • Headline prices are 'as low as' rates (asterisked) — your actual monthly cost may be higher
  • No LegitScript certification displayed; marketing leans heavily on testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard